

ALK
RET
ROS1

ARCHER™ FUSIONPlex™

Archer™ FusionPlex™ ALK RET ROS1 Panel v2

The FusionPlex ALK, RET, ROS1 panel v2 is a targeted sequencing assay that simultaneously detects and identifies fusions of human ALK, RET and ROS1 genes, as well as point mutations that are reported to be associated with resistance to tyrosine kinase inhibitors.

- Simultaneous detection of gene fusions and point mutations provides relevant information up front
- Automated analysis reduces need for informatics support
- Multiplex assay reduces need for reflex testing
- Verified performance with FFPE samples
- Low assay input – only 20ng of nucleic acid needed

For Research Use Only. Not for use in diagnostic procedures.

Assay Targets

Gene	Fusion Exons	Point Mutations
ALK	19, 20, 21, 22	C1156Y, G1202R, D1203N, S1206Y, F1174L, L1196M, G1269A
RET	8, 9, 10, 11, 12, 13	V804M/L
ROS1	31, 32, 33, 34, 35, 36, 37	N/A

No More FISHing

FusionPlex assays reduce the turnaround time needed to test for gene translocations in your laboratory. By providing multiple datapoints from a single sample, traditional testing workflows can be consolidated into a single streamlined process.

Once the library is sequenced, the automated Archer Analysis Pipeline creates a report of observed fusions and point mutations from each sample, along with QC and additional statistics that support the reported results.

Replacing subjective, single-plex assays, FusionPlex assays provide the comprehensive information needed to understand genetic mutations in an easy-to-use, scalable format.

Learn more about the FusionPlex ALK, RET, ROS1 Panel at
www.archerdx.com/alk-fusion-assay